scholarly journals Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Shih Yea Sylvia Wu ◽  
Bridget Faire ◽  
Edward Gane
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Kidney Injury ◽  
Complete Recovery ◽  
Final Diagnosis ◽  
Community Acquired Pneumonia ◽  
Drug Induced ◽  
First Case ◽  
Life Threatening

VIEKIRA PAK (ritonavir-boosted paritaprevir/ombitasvir and dasabuvir) is an approved treatment for compensated patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. This oral regimen has minimal adverse effects and is well tolerated. Cure rates are 97% in patients infected with HCV GT 1a and 99% in those with HCV GT 1b. We report the first case of life-threatening allergic pneumonitis associated with VIEKIRA PAK. This unexpected serious adverse event occurred in a 68-year-old Chinese female with genotype 1b chronic hepatitis C and Child-Pugh A cirrhosis. One week into treatment with VIEKIRA PAK without ribavirin, she was admitted to hospital with respiratory distress and acute kidney injury requiring intensive care input. She was initially diagnosed with community acquired pneumonia and improved promptly with intravenous antibiotics and supported care. No bacterial or viral pathogens were cultured. Following complete recovery, she recommenced VIEKIRA PAK but represented 5 days later with more rapidly progressive respiratory failure, requiring intubation and ventilation, inotropic support, and haemodialysis. The final diagnosis was drug induced pneumonitis.

scholarly journals Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir

2018 ◽  
Vol 2 (10) ◽  
pp. 1172-1178 ◽  
Author(s):  
Patrick R. Brown ◽  
Omar Sadiq ◽  
Alexander Weick ◽  
Adrienne Lenhart ◽  
Mohammad Elbatta ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Kidney Injury ◽  
Chronic Hepatitis C Virus

scholarly journals De NovoFibrillary Glomerulonephritis (FGN) in a Renal Transplant with Chronic Hepatitis C

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Edward J. Filippone ◽  
Christine Chmielewski ◽  
Rakesh Gulati ◽  
Eric Newman ◽  
John L. Farber
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Chronic Hepatitis C ◽  
Renal Transplant Patient ◽  
Renal Allograft ◽  
De Novo ◽  
First Case ◽  
Transplant Glomerulopathy

Chronic hepatitis C viremia (HepC) has been associated with numerous renal manifestations both in native kidneys and in the setting of renal transplantation. Glomerulonephritis (GN) of the renal allograft in the setting of HepC most commonly manifests as type 1 membranoproliferative GN (MPGN), either representing recurrence of the original disease or arisingde novo. Other GNs were reported after transplantation in the patient with HepC including membranous nephropathy and thrombotic microangiopathy, as well as an enhanced susceptibility to transplant glomerulopathy. We describe the first case ofde novofibrillary GN in a renal transplant patient with HepC where the primary renal disease was biopsy proven type 1 MPGN. We discuss this relationship in detail.

scholarly journals Serum miR-122 and Human Genomic DNA in Patients With Drug-Induced Acute Liver Failure or With Chronic Hepatitis C

2011 ◽  
Vol 140 (5) ◽  
pp. S-951
Author(s):  
R Kenton Devine ◽  
Hejun Yuan ◽  
Mamta K. Jain ◽  
Corron M. Sanders ◽  
Nahid Attar ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Chronic Hepatitis C ◽  
Genomic Dna ◽  
Drug Induced ◽  
Human Genomic ◽  
Human Genomic Dna

scholarly journals Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir

2015 ◽  
Vol 45 (10) ◽  
pp. E156-E160 ◽  
Author(s):  
Akira Okajima ◽  
Kanji Yamaguchi ◽  
Hiroyoshi Taketani ◽  
Tasuku Hara ◽  
Hiroshi Ishiba ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Injury ◽  
Chronic Hepatitis C ◽  
Drug Induced ◽  
Drug Induced Liver Injury

LIFE-THREATENING THYROTOXICOSIS INDUCED BY COMBINATION THERAPY WITH PEG-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C

2005 ◽  
Vol 11 (2) ◽  
pp. 135-139 ◽  
Author(s):  
Yong Q. Lin ◽  
Xiangbing Wang ◽  
Meena S. Murthy ◽  
Sumon Agarwala
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Life Threatening

scholarly journals Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Omar Y. S. Mousa ◽  
Rossa Khalaf ◽  
Rhonda L. Shannon ◽  
Chukwuma I. Egwim ◽  
Scott A. Zela ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Maculopapular Rash ◽  
Virus Genotype ◽  
Drug Induced ◽  
Gradual Improvement ◽  
Complication Risk ◽  
Systemic Symptoms ◽  
High Index Of Suspicion

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare yet severe adverse drug-induced reaction with up to 10% mortality rate. Recent clinical trials reported an association between DRESS and telaprevir (TVR), an NS3/4A protease inhibitor of chronic hepatitis C (CHC) virus genotype 1. Its diagnosis is challenging given the variable pattern of cutaneous eruption and the myriad internal organ involvement. We present two patients who are middle-aged, obese, and white with CHC cirrhosis. They both developed a progressive diffuse, painful pruritic maculopapular rash at weeks 8 and 10 of CHC therapy with TVR, Peg-Interferon alfa-2a, and Ribavirin. They had no exposures to other medications that can cause this syndrome. Physical exam and labs and skin biopsy supported a “Definite” clinical diagnosis of DRESS, per RegiSCAR criteria. Thus Telaprevir-based triple therapy was discontinued and both patients experienced rapid resolution of the systemic symptoms with gradual improvement of eosinophilia and the skin eruption. These two cases illustrate the paramount importance of having a high index of suspicion for TVR-induced DRESS, critical for early diagnosis. Immediate discontinuation of TVR is essential in prevention of a potentially life-threatening complication. Risk factors for development of DRESS in patients receiving TVR remain to be elucidated.

scholarly journals Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C

2006 ◽  
Vol 20 (10) ◽  
pp. 661-663 ◽  
Author(s):  
Yvette Leung ◽  
Stefan J Urbanski ◽  
Lynn Schindel ◽  
Robert P Myers
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Ischemic Colitis ◽  
Infected Patient ◽  
Metastatic Cancer ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
First Case

Rare cases of ischemic colitis associated with interferon-alpha (IFN-α) treatment for chronic hepatitis C (HCV) infection and metastatic cancer have been reported. The present study describes the first case of ischemic colitis attributable to pegylated IFN-α and ribavirin combination therapy in an HCV-infected patient after 34 weeks of treatment. The clinical presentation, endoscopic appearance and histopathology of the colon were consistent with ischemic colitis, and the patient’s symptoms rapidly resolved with cessation of therapy. The association between the therapy and the pathogenesis of ischemic colitis is unclear, but immunoregulatory, vasospastic and procoagulant mechanisms have been proposed. Physicians should be aware of this complication, and should consider it in any HCV-infected patient taking pegylated IFN-α and ribavirin who develops abdominal discomfort and gastrointestinal bleeding.

scholarly journals Graham Little-Lassueur Syndrome with Hypertrophic Lichen Planus in a Patient with Chronic Hepatitis C

2016 ◽  
Vol 62 (1) ◽  
pp. 149-151
Author(s):  
Mihail Alexandru Badea ◽  
Florin Buicu ◽  
Anton Mihai Ţilea ◽  
Iudita Maria Badea ◽  
Andreea Luciana Chiotoroiu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Salicylic Acid ◽  
Hepatitis C ◽  
Skin Biopsy ◽  
Chronic Hepatitis C ◽  
Lichen Planus ◽  
Narrow Band ◽  
Lichen Planopilaris ◽  
First Case ◽  
Erythematous Plaques

Abstract Graham Little-Lassueur Syndrome (GLLS) is considered a form of lichen planopilaris which associates follicular lichen planus, cicatricial alopecia of the scalp and noncicatricial alopecia of the axillary and/or pubic regions. We present the case of a 47 years old female patient, known for 5 years with chronic hepatitis C and a poor therapeutic control of the disease due to Interferon intolerance. She presented to our clinic for the occurrence on the shins of some well-defined, intensely pruritic erythematous plaques, covered with thick scales, with a verrucous appearance, accompanied by excoriations. The skin biopsy reveal hypertrophic lichen planus on the shins and lichen planopilaris on the scalp. The patient was treated with systemic antihystamines, topical corticosteroids and salicylic acid under occlusion, emollients, phototherapy UVB narrow band 4 sessions/week for 3 weeks, cryotherapy. From our knowledge this is the first case of GLLS associated with chronic viral hepatis C.

scholarly journals Impact of Acute Kidney Injury on Survival in Patients With Chronic Hepatitis C

2020 ◽  
Author(s):  
Hankyu Jeon ◽  
Jae Heon Kim ◽  
Sang Soo Lee ◽  
Hee Jin Kim ◽  
Ra Ri Cha ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Cox Regression ◽  
Kidney Injury ◽  
Hcv Infection ◽  
Decompensated Cirrhosis ◽  
Cox Regression Analysis ◽  
Overall Mortality

Abstract Background: Acute kidney injury (AKI) is expected to occur commonly in patients with chronic hepatitis C. In addition, AKI may affect the survival of patients with chronic hepatitis C. However, few studies are available on this topic. We aimed to evaluate the incidence of AKI in patients with chronic hepatitis C and investigate the factors related to overall mortality. Methods: Between January 2005 and December 2018, 1252 patients with chronic hepatitis C virus (HCV) infection were retrospectively enrolled at two centers. Of them, 1008, 123, and 121 patients had chronic hepatitis (CH), compensated cirrhosis (Com-LC), and decompensated cirrhosis (Decom-LC) or hepatocellular carcinoma (HCC) at entry, respectively. Results: Over a mean follow-up period of 5.2 years, 285 patients developed AKI, with an incidence rate of 4.35 per 100 person-years. The incidence of AKI increased gradually with progression of chronic hepatitis C: CH (3.32 per 100 person-years), Com-LC (5.86 per 100 person-years), and Decom-LC or HCC (17.28 per 100 person-years). Patients without AKI showed a better survival rate than patients with AKI (P < 0.001). In multivariate Cox regression analysis, AKI (hazard ratio, 6.66; 95% confidence interval, 4.26–10.41) remained an independent risk factor for overall mortality. Conclusion: AKI is common in patients with chronic HCV infection and is associated with significant overall mortality. Therefore, clinicians should carefully monitor the occurrence of AKI, which is an important predictor of mortality in patients with chronic hepatitis C.

Sign in / Sign up

Export Citation Format

Share Document